Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) Stock Short Interest Climbs 313.3%

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 141,864 shares, an increase of 313.3% from the September 30th total of 34,322 shares. Approximately 0.9% of the shares of the company are sold short. Based on an average daily trading volume, of 60,205 shares, the days-to-cover ratio is presently 2.4 days.

Radiopharm Theranostics Stock Performance

Shares of NASDAQ RADX traded up $0.15 during mid-day trading on Thursday, reaching $1.10. 32,477 shares of the company were exchanged, compared to its average volume of 90,178. The company’s 50-day simple moving average is $1.64 and its 200-day simple moving average is $3.72. Radiopharm Theranostics has a twelve month low of $0.90 and a twelve month high of $16.25.

Radiopharm Theranostics (NASDAQ:RADX) last announced its quarterly earnings results on Friday, July 31st. The company reported ($0.81) EPS for the quarter. The company had revenue of $0.49 million for the quarter. On average, sell-side analysts anticipate that Radiopharm Theranostics will post -3.23 EPS for the current year.

Hedge Funds Weigh In On Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. Hsbc Holdings PLC acquired a new stake in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 191,624 shares of the company’s stock, valued at approximately $1,007,000. Hsbc Holdings PLC owned approximately 1.62% of Radiopharm Theranostics at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Radiopharm Theranostics currently has an average rating of “Hold” and a consensus price target of $11.00.

About Radiopharm Theranostics

Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company focused on developing radiopharmaceutical products for the diagnosis and treatment of cancer. Its approach combines tumor-targeting molecules with radioactive isotopes to create imaging agents for positron emission tomography and therapeutic candidates designed to deliver radiation directly to cancer cells.

The company is developing a pipeline of diagnostic and therapeutic radiopharmaceuticals intended to address solid tumors and other difficult-to-treat cancers.